Sanofi (SNY)
| Market Cap | 116.94B |
| Revenue (ttm) | 53.89B |
| Net Income (ttm) | 10.69B |
| Shares Out | 1.22B |
| EPS (ttm) | 8.67 |
| PE Ratio | 10.94 |
| Forward PE | 9.98 |
| Dividend | $1.60 (3.31%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 807,681 |
| Open | 48.34 |
| Previous Close | 48.32 |
| Day's Range | 48.16 - 48.49 |
| 52-Week Range | 44.62 - 60.12 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 61.50 (+27.17%) |
| Earnings Date | Jan 29, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $61.5, which is an increase of 27.17% from the latest price.
News
This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.
Sanofi agrees to acquire Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.
Sanofi to acquire US biotech Dynavax for $2.2 billion
French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an agr...
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a ...
Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP...
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduce...
Sanofi: Information concerning the total number of voting rights and shares - November 2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump's four requests, establishing a framework for lower prices ...
Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript
Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and sell the biotech company's experimental Alzheimer's disease treat...
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why
Sanofi faces a setback as tolebrutinib fails its Phase 3 PPMS trial, halting regulatory pursuit for this indication. Meanwhile, an approval decision on the candidate has also been delayed. SNY's growt...
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ: SNY). The new agreement is built on the existing relationship between the two companie...
Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion
Dren Bio, a private biotech company, said on Monday it has entered into a strategic collaboration with Sanofi to develop therapies for autoimmune diseases in a deal worth up to $1.7 billion.
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy.
Sanofi shares slide as FDA delays MS drug decision and late-stage trial disappoints
Shares of French pharmaceutical group Sanofi fell sharply on Monday after the company flagged another delay to a US regulatory decision for its experimental multiple sclerosis drug tolebrutinib and re...
Sanofi stock slumps after two setbacks on multiple-sclerosis drug
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won't be completed by the end of the year and that a trial for a different form ...
Sanofi flags delay in FDA's decision on tolebrutinib, shares fall
French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug to treat multiple sclerosis was expected to be delayed until the first quar...
Sanofi Multiple Sclerosis Drug Hit by Double Setback
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn't hit its main goal.
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to o...
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regu...
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs
The National Medical Products Administration (NMPA) in China has approved Sanofi SA's (NASDAQ: SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplaci...